News
June 10, 2026
AbTherx Expands Platform and Leadership Team to Unlock Antibody Discovery...
Expanding platform with next-generation VHH, lambda common light chain, and specialized long-CDR3 technologies Mountain View, Calif. – June 10, 2026 – AbTherx, Inc., ... Read More »
May 11, 2026
First Antibody Derived from AbTherx Platform Advances into Clinical Development
Achieving clinical validation in under three years underscores the efficiency of AbTherx’s platform Mountain View, Calif. – May 11, 2026 – AbTherx, Inc., a privately ... Read More »
January 8, 2026
AbTherx and Red Queen Bio Partner on Therapeutic Antibody Discovery
Partnership has already generated high-quality, AI-ready data in less than three months Mountain View, Calif. – January 8, 2026 – AbTherx today announced a therapeuti... Read More »
September 23, 2025
AbTherx and Dragonfly Therapeutics Expand Antibody Discovery Partnership
Expansion comes after multi-target evaluation with Atlas™ Full Human Diversity Mice demonstrated superior performance in head-to-head study Mountain View, Calif. – Se... Read More »
June 16, 2025
AbTherx and GPCR Therapeutics Announce a Strategic Collaboration to Discover...
Partnership combines AbTherx’s proprietary Atlas™ Long CDR3 Technology with GPCR Therapeutics’ deep expertise in GPCR biology to discover and develop antibodies for n... Read More »
